FASN and ovarian cancer: In line with these findings, inhibition of glutaminase sensitized cisplatin-resistant ovarian cancers to chemotherapy (110, 110) and also the inhibition of FASN with orlistat enhanced the efficacy of cisplatin in ovarian cancers (111).